Jianhua Peng

Jianhua Peng

Auto-generated profile, based on publicly available information

Jianhua Peng

Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, CHN

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in IEEE Access
Verified
Journal Article
Open access
JLJinsong Li
Jinsong Li
JPJianhua Peng
Jianhua Peng
SLShu-Xin Liu
Shu-Xin Liu
XJXinsheng Ji
Xinsheng Ji
XLXing Li
Xing Li
XHXinxin Hu
Xinxin Hu
Link prediction in directed networks has always been a hot topic in many fields including network science, information system and data mining. Intuitively, once links are endowed with certain orientations, their reciprocate nature can potentially provide extra information for guiding link prediction. However, the role of reciprocal links in the formation of directed closure triads and their ability to enhance link prediction accuracy are not thoroughly investigated yet in existing works. In this paper, we first design an empirical test to investigate the role of reciprocal links in different types of directed networks by taking advantage of null models. Subsequently, based on solid evidence of the empirical test, two novel weighting mechanisms for link prediction are proposed utilizing reciprocity as extra information. The performance of proposed methods is comprehensively studied on eight realistic networks compared with several groups of benchmarks. Experimental results indicate that the proposed methods are more effective and robust than two state-of-the-art weighting methods and eight well-performing similarity indices.

1 September 2011 in International Journal of Bifurcation and Chaos
Verified
Journal Article
Closed access
XZXiaoming Zhang
Xiaoming Zhang
JCJufang Chen
Jufang Chen
JPJianhua Peng
Jianhua Peng

1 November 1995 in Medical & Biological Engineering & Computing
Verified
Journal Article
Closed access
PDF file
BLBingzheng Liu
Bingzheng Liu
JPJianhua Peng
Jianhua Peng
YLYiwei Liu
Yiwei Liu

16 September 2020 in International Journal of Modern Physics C
Verified
Journal Article
Closed access
PDF file
JLJinsong Li
Jinsong Li
JPJianhua Peng
Jianhua Peng
SLShu-Xin Liu
Shu-Xin Liu
KWKai Wang
Kai Wang
CLCong Li
Cong Li

30 July 2023 in Cureus
Verified
Journal Article
Open access
PDF file
HLHong-Jin Liang
Hong-Jin Liang
XJXiao-Min Jiang
Xiao-Min Jiang
FSFeng-Cai Shen
Feng-Cai Shen
JPJian-Hua Peng
Jian-Hua Peng
DWDan-Min Wang
Dan-Min Wang
LLLing Lin
Ling Lin
Background: Studies investigating the association between single nucleotide polymorphisms (SNPs) of tumor necrosis factor-alpha (TNFα) and the efficacy of adalimumab (ADA) in ankylosing spondylitis (AS) therapy have reported conflicting results. We aimed to investigate the value of SNP typing of TNFα in predicting the efficacy of ADA in AS. Materials and methods: Eighty patients with active AS who received ADA treatment were followed up for 24 weeks. Six known SNPs of TNFα (+489G/A, -238G/A, -308G/A, -857C/T, -863C/A, and -1031C/T) were subjected to the SNaPshot SNP typing method, which has been proven to be a reliable, efficient, and cost-effective method for detecting SNPs. The relationship between each SNP genotype and the therapeutic efficacy of ADA was analyzed. Results: At the end of the 24-week follow-up, 58.8% of the patients with AS achieved Assessment of SpondyloArthritis International Society (ASAS) partial remission (PR), 67.5% of the patients achieved the criteria of an ASAS40 response (40% improvement on indices), and 53.8% of the patients achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement (MI). The univariate analysis showed that patients with AS carrying the TNFα +489 A allele were more likely to achieve ASAS-PR, ASAS40 response criteria, and ASDAS-MI after ADA treatment. In the multivariate regression analysis, the TNFα +489 A allele was an independent factor influencing the efficacy of ADA in treating AS (ASAS-PR odds ratio (OR) = 2.66, 95% confidence interval (CI) = 1.01-7.01; ASAS40 OR = 4.56, 95% CI = 1.39-15.00; ASDAS-MI OR = 3.31, 95% CI = 1.02-10.69). Conclusions: The patients carrying the TNFα +489 A allele may be more likely to experience better therapeutic efficacy and achieve the treatment target (ASAS-PR, ASAS40 response, or ASDAS-MI) after receiving ADA treatment. Detection of TNFα +489 G/A may predict the therapeutic efficacy of ADA, which can be used in clinical practice to tailor treatment for individual patients with AS. Further studies with larger sample sizes and longer follow-up periods with imaging evaluation are needed to verify our findings.